GGrantIndex
Sort

130,381 grants matching hiv

Project 1 - Development of mRNA Immunogens for Protective Antibody Induction

$942,168
Barton F Haynes · Duke University · U19 · FY2020 · AI

The Effectiveness of Automated Multimodal Imaging in High Grade Squamous Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV: An International Trial

$942,063
Sharmila Anandasabapathy · Baylor College Of Medicine · R01 · FY2025 · CA

Critical Path IND-enabling Studies, Regulatory, and Product Development

$942,042
Robert Walter Buckheit · Imquest Biosciences · U19 · FY2012 · AI

Reducing Latent Viral Reservoirs in Infant Macaques

$941,882
Nancy Logan Haigwood · Oregon Health & Science University · R01 · FY2014 · HD

Single-Cell Transcriptomics of Non-Activated Latently Infected T cells Isolated from HIV+ Drug Users

$941,806
Melanie Maria Ott · J. David Gladstone Institutes · R33 · FY2023 · DA

Multimodal Imaging of NeuroHIV Dynamics (MIND): An Omaha-Pittsburgh Consortium

$941,747
Tony W. Wilson · University Of Nebraska Medical Center · R01 · FY2020 · MH

UAB AIDS/HIV INTERNATIONAL TRAINING &RESEARCH PROGRAM

$941,734
University Of Alabama At Birmingham · D43 · FY2002 · TW

Preclinical evaluation of HIV rectal microbicides

$941,685
University Of California Los Angeles · U19 · FY2004 · AI

Pathogenic determinants of the SIV envelope transmembrane cytoplasmic domain

$941,644
James A Hoxie · University Of Pennsylvania · R01 · FY2009 · AI

Administrative Core

$941,592
John T. West · Lsu Health Sciences Center · P20 · FY2025 · GM

Study of Tumor Pathogenesis and Development of Therapies for AIDS Malignancies

$941,513
Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

PEDIATRIC AIDS CLINICAL TRIALS GROUP

$941,493
Columbia University Health Sciences · U01 · FY2000 · AI

Evaluation of the Immunogenicity and Efficacy of a MVA-HIV Prime, gp145 HIV protein/ALFA-adjuvanted Boost Vaccine Regimen with SHIV-CH505 Challenge in Male Rhesus Macaques

$941,082
Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2018 · AI

Optimizing eCD4-Ig for eradication and a functional cure

$941,073
Michael R. Farzan · Scripps Florida · R01 · FY2018 · AI

Optimizing eCD4-Ig for eradication and a functional cure

$941,035
Michael R. Farzan · Scripps Florida · R01 · FY2020 · AI

The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)

$940,992
Patrick M McDonough · Vala Sciences, Inc. · R44 · FY2022 · MH

Delaware Valley Node of the Clinical Trials Network

$940,977
George E Woody · University Of Pennsylvania · U10 · FY2014 · DA

Ohio Valley Node-Network (OVNN) of the NIDA Clinical Trials Network

$940,908
T John Winhusen · University Of Cincinnati · UG1 · FY2018 · DA

New Pharmacologic Measures of ART Adherence and Exposure: Pathway to Clinical Implementation

$940,803
Jose Ramon Castillo-Mancilla · University Of Colorado Denver · R01 · FY2021 · AI

Pre-clinical progressive selection of a tenofovir analog enema

$940,730
Justin S. Hanes · Johns Hopkins University · U19 · FY2016 · AI

A new model of accelerated immune aging in HIV-infected drug users

$940,675
Melanie Maria Ott · J. David Gladstone Institutes · DP1 · FY2015 · DA

HIV without AIDS: A Radically Different Approach to Help the Developing World

$940,675
Warner C Greene · J. David Gladstone Institutes · DP1 · FY2015 · DA

Structural characterization of MPER-TM immunogens

$940,588
Ellis L Reinherz · Dana-Farber Cancer Inst · P01 · FY2024 · AI

MAPs for Peds: Development of a Microarray Patch for Delivery of Long-Acting Antiretrovirals for Treatment of Pediatric HIV Infection

$940,558
Robert Kwai Ming Choy · Path · R33 · FY2022 · AI

IMMUNE CONTROL OF HIV REPLICATION

$940,551
Massachusetts General Hospital · R01 · FY2002 · AI